$421.39
-1.24-0.29%
al cierre: -
$421.39
0.000.00%
After hour: Oct 24, 4:00 PM EDT
Comments
Loading...
Vertex Pharmaceuticals Actividad de operaciones con información privilegiada
VRTXNASDAQ
Actividad de operaciones de insiders
Sigue la actividad de operaciones con información privilegiada más reciente de Vertex Pharmaceuticals. Mantente informado sobre las compras, ventas e impacto en el mercado recientes de las acciones de Vertex Pharmaceuticals.
¿Qué es la actividad interna?
La actividad de uso de información privilegiada involucra a personas con información privilegiada de la empresa, como ejecutivos, directores y empleados, que participan en transacciones con acciones de su propia empresa. Las transacciones de compra y venta de los iniciados proporcionan información valiosa sobre su confianza en el desempeño futuro de la empresa.
¿Qué están haciendo Vertex Pharmaceuticals Inc los iniciados?
En Vertex Pharmaceuticals Inc, la reciente actividad interna ha llamado la atención. Durante los últimos 30 días, los insiders han informado que han vendido un total de 1.95K acciones por valor de $784.12K, mientras tanto, los insiders han no reportar compras en los últimos 30 días.
Compras y ventas recientes notables de información privilegiada
- El agosto 7, 2025, Reshma Kewalramani, la empresa CEO & PRESIDENT purchased 10K acciones por $389.58 cada una.
- El agosto 7, 2025, BRUCE SACHS, la empresa DIRECTOR purchased 5K acciones por $389.68 cada una.
- El agosto 29, 2025, Sangeeta Bhatia, la empresa DIRECTOR sold 266 acciones por $386.69 cada una.
Estadísticas de propiedad de Vertex Pharmaceuticals Inc
Acciones en circulación
256.391M
Acciones en manos de personas con información privilegiada
2.531M
Porcentaje de acciones en manos de personas con información privilegiada
0.99%
Acciones en manos de instituciones
226.006M
Porcentaje de acciones en manos de instituciones
88.1%
Oct 03, 2025 | EVP AND CHIEF LEGAL OFFICER | -1.95K | $401.50 | -$784.12K | SELL | -11.09% | 15.65K | Oct 01 - Oct 02 | ||
Aug 29, 2025 | DIRECTOR | -266.00 | $386.69 | -$102.86K | SELL | -5.51% | 4.57K | Aug 27 | ||
Aug 07, 2025 | CEO & PRESIDENT | 10.00K | $389.58 | $3.90M | BUY | 9.44% | 115.97K | Aug 06 | ||
Aug 07, 2025 | DIRECTOR | 5.00K | $389.68 | $1.95M | BUY | 12.50% | 45.00K | Aug 06 | ||
May 19, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -52.00 | $424.69 | -$22.08K | SELL | -0.22% | 23.28K | May 15 | ||
May 05, 2025 | DIRECTOR | 396.00 | $505.86 | -$202.34K | GRANT | 8.93% | 4.83K | May 01 - May 02 | ||
Mar 17, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $510.00 | -$1.65M | SELL | -12.19% | 23.28K | Mar 13 | ||
Mar 12, 2025 | EVP & CHIEF FINANCIAL OFFICER | -3.30K | $500.00 | -$1.65M | SELL | -6.00% | 51.67K | Mar 10 | ||
Mar 12, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -3.24K | $499.99 | -$1.62M | SELL | -5.95% | 51.24K | Mar 10 | ||
Mar 12, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $500.00 | -$1.62M | SELL | -10.86% | 26.51K | Mar 10 | ||
Mar 06, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -4.06K | $485.49 | -$1.97M | SELL | -6.93% | 54.48K | Mar 04 | ||
Mar 05, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -3.23K | $490.00 | -$1.58M | SELL | -9.80% | 29.74K | Mar 03 | ||
Feb 28, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -5.49K | $479.20 | -$2.63M | SELL | -8.58% | 58.54K | Feb 26 - Feb 27 | ||
Feb 28, 2025 | EVP, CHIEF TECHNICAL OPS. OFF. | -5.13K | $477.41 | -$2.45M | SELL | -20.96% | 19.35K | Feb 26 - Feb 27 | ||
Feb 28, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -7.23K | $479.68 | -$3.47M | SELL | -17.98% | 32.97K | Feb 26 - Feb 27 | ||
Feb 26, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $483.05 | -$1.77M | SELL | -5.41% | 64.03K | Feb 24 - Feb 25 | ||
Feb 26, 2025 | EVP, CHIEF TECHNICAL OPS. OFF. | -3.42K | $482.08 | -$1.65M | SELL | -12.27% | 24.48K | Feb 24 - Feb 25 | ||
Feb 26, 2025 | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $482.08 | -$825.32K | SELL | -15.85% | 9.09K | Feb 24 - Feb 25 | ||
Feb 26, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -4.82K | $482.87 | -$2.33M | SELL | -10.70% | 40.20K | Feb 24 - Feb 25 | ||
Feb 24, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -1.11K | $480.00 | -$533.28K | SELL | -2.41% | 45.02K | Feb 20 | ||
Feb 19, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -2.54K | $462.65 | -$1.17M | SELL | -3.61% | 67.69K | Feb 14 - Feb 18 | ||
Feb 19, 2025 | EVP AND CHIEF LEGAL OFFICER | -3.16K | $459.06 | -$1.45M | SELL | -15.22% | 17.61K | Feb 14 - Feb 18 | ||
Feb 19, 2025 | SVP & CHIEF ACCOUNTING OFFICER | -1.24K | $458.90 | -$566.74K | SELL | -10.26% | 10.80K | Feb 14 - Feb 18 | ||
Feb 12, 2025 | EVP, CHIEF REG. & QUALITY OFF. | -2.45K | $466.95 | -$1.15M | SELL | -3.69% | 64.02K | Feb 10 - Feb 11 | ||
Feb 12, 2025 | EVP AND CHIEF LEGAL OFFICER | -5.07K | $462.48 | -$2.34M | SELL | -23.67% | 16.33K | Feb 10 - Feb 11 | ||
Feb 12, 2025 | EVP, CHIEF TECHNICAL OPS. OFF. | -2.62K | $462.55 | -$1.21M | SELL | -10.15% | 23.23K | Feb 10 - Feb 11 | ||
Feb 12, 2025 | SVP & CHIEF ACCOUNTING OFFICER | -1.97K | $462.28 | -$909.30K | SELL | -16.50% | 9.95K | Feb 10 - Feb 11 | ||
Nov 19, 2024 | EVP, CHIEF SCIENTIFIC OFFICER | -15.00 | $478.56 | -$7.18K | SELL | -0.06% | 25.81K | Nov 15 | ||
Nov 13, 2024 | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $518.27 | -$1.55M | SELL | -6.36% | 44.14K | Nov 11 | ||
Nov 12, 2024 | CEO & PRESIDENT | -15.20K | $515.00 | -$7.83M | SELL | -16.71% | 75.77K | Nov 08 | ||
Oct 03, 2024 | EVP AND CHIEF LEGAL OFFICER | -1.63K | $463.66 | -$755.31K | SELL | -8.91% | 16.65K | Oct 01 - Oct 02 | ||
Sep 04, 2024 | EXECUTIVE CHAIRMAN | -3.78K | $499.00 | -$1.89M | SELL | -26.61% | 10.43K | Aug 30 | ||
Sep 04, 2024 | DIRECTOR | 0.00 | $326.37 | -$224.33K | SELL-OPTIONS | 0.00% | 4.43K | Aug 30 | ||
Aug 12, 2024 | DIRECTOR | 0.00 | $309.51 | -$405.11K | SELL-OPTIONS | 0.00% | 4.43K | Aug 08 | ||
Aug 08, 2024 | EVP AND CMO | -2.28K | $476.75 | -$1.09M | SELL | -8.93% | 23.26K | Aug 07 | ||
Aug 02, 2024 | DIRECTOR | 0.00 | $316.86 | -$2.02M | SELL-OPTIONS | 0.00% | 40.00K | Aug 01 | ||
Aug 01, 2024 | CEO & PRESIDENT | -15.20K | $505.00 | -$7.68M | SELL | -14.32% | 90.97K | Jul 30 | ||
Jul 25, 2024 | EVP AND CMO | -2.28K | $488.46 | -$1.11M | SELL | -8.20% | 25.54K | Jul 24 | ||
Jul 24, 2024 | CEO & PRESIDENT | -15.20K | $497.00 | -$7.56M | SELL | -12.52% | 106.17K | Jul 22 | ||
Jul 12, 2024 | EVP AND CMO | -2.28K | $487.34 | -$1.11M | SELL | -7.58% | 27.82K | Jul 10 | ||
Jun 28, 2024 | EVP AND CMO | -2.28K | $471.72 | -$1.08M | SELL | -7.04% | 30.10K | Jun 26 | ||
Jun 13, 2024 | EVP AND CMO | -2.28K | $478.00 | -$1.09M | SELL | -6.58% | 32.38K | Jun 12 | ||
Jun 13, 2024 | EVP, CHIEF TECHNICAL OPS. OFF. | -14.11K | $479.91 | -$6.77M | SELL | -46.91% | 15.97K | Jun 11 - Jun 12 | ||
Jun 05, 2024 | EVP & CHIEF FINANCIAL OFFICER | -3.25K | $460.00 | -$1.50M | SELL | -6.45% | 47.14K | Jun 03 | ||
Jun 05, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -2.17K | $460.00 | -$1.00M | SELL | -4.24% | 49.10K | Jun 03 | ||
Jun 03, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -4.60K | $441.99 | -$2.03M | SELL | -8.23% | 51.27K | May 30 - May 31 | ||
May 31, 2024 | EVP AND CMO | -2.28K | $445.56 | -$1.02M | SELL | -6.17% | 34.66K | May 29 | ||
May 30, 2024 | EVP & CHIEF FINANCIAL OFFICER | -3.25K | $454.79 | -$1.48M | SELL | -6.06% | 50.39K | May 28 | ||
May 29, 2024 | CEO & PRESIDENT | 0.00 | $322.26 | -$421.72K | SELL-OPTIONS | 0.00% | 121.37K | May 24 | ||
May 24, 2024 | DIRECTOR | 0.00 | $270.75 | -$2.51M | SELL-OPTIONS | 0.00% | 40.00K | May 22 | ||
May 22, 2024 | CEO & PRESIDENT | -15.20K | $447.00 | -$6.80M | SELL | -11.13% | 121.37K | May 20 | ||
May 17, 2024 | EVP CHIEF PATIENT & EXT AF OFF | -32.00 | $430.93 | -$13.79K | SELL | -0.06% | 56.21K | May 15 | ||
May 17, 2024 | EVP, COO | -69.00 | $430.93 | -$29.73K | SELL | -0.14% | 49.83K | May 15 | ||
May 17, 2024 | EVP, CHIEF SCIENTIFIC OFFICER | -54.00 | $430.93 | -$23.27K | SELL | -0.21% | 25.81K | May 15 | ||
May 03, 2024 | DIRECTOR | 534.00 | $402.95 | -$188.18K | GRANT | 13.69% | 4.43K | May 01 - May 02 | ||
Apr 03, 2024 | SVP & CHIEF ACCOUNTING OFFICER | -465.00 | $418.56 | -$194.63K | SELL | -5.84% | 7.50K | Apr 01 - Apr 02 | ||
Feb 27, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $431.20 | -$1.58M | SELL | -6.16% | 55.80K | Feb 23 - Feb 26 | ||
Feb 27, 2024 | EVP CHIEF PATIENT & EXT AF OFF | -5.47K | $428.45 | -$2.34M | SELL | -8.12% | 61.89K | Feb 23 - Feb 26 | ||
Feb 27, 2024 | EVP, CHIEF TECHNICAL OPS. OFF. | -2.54K | $429.67 | -$1.09M | SELL | -13.71% | 15.97K | Feb 23 - Feb 26 | ||
Feb 27, 2024 | EVP, COO | -9.75K | $428.65 | -$4.18M | SELL | -16.36% | 49.83K | Feb 23 - Feb 26 | ||
Feb 27, 2024 | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $428.65 | -$733.42K | SELL | -17.68% | 7.96K | Feb 23 - Feb 26 | ||
Feb 27, 2024 | EVP, GLOBAL RESEARCH AND CSO | -8.21K | $428.65 | -$3.52M | SELL | -24.13% | 25.81K | Feb 23 - Feb 26 | ||
Feb 23, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -360.00 | $421.77 | -$151.84K | SELL | -0.60% | 59.47K | Feb 21 | ||
Feb 23, 2024 | EVP CHIEF PATIENT & EXT AF OFF | -3.19K | $421.77 | -$1.35M | SELL | -4.52% | 67.36K | Feb 21 | ||
Feb 23, 2024 | EVP, CHIEF TECHNICAL OPS. OFF. | -1.20K | $421.77 | -$506.55K | SELL | -6.09% | 18.51K | Feb 21 | ||
Feb 23, 2024 | EVP, COO | -3.60K | $421.77 | -$1.52M | SELL | -5.70% | 59.58K | Feb 21 | ||
Feb 23, 2024 | EVP, GLOBAL RESEARCH AND CSO | -3.00K | $421.77 | -$1.27M | SELL | -8.11% | 34.02K | Feb 21 | ||
Feb 21, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -8.35K | $422.44 | -$3.53M | SELL | -12.25% | 59.83K | Feb 16 - Feb 20 | ||
Feb 21, 2024 | EVP CHIEF PATIENT & EXT AF OFF | -10.38K | $421.82 | -$4.38M | SELL | -12.82% | 70.55K | Feb 16 - Feb 20 | ||
Feb 21, 2024 | EVP, CHIEF TECHNICAL OPS. OFF. | -3.43K | $422.13 | -$1.45M | SELL | -14.81% | 19.71K | Feb 16 - Feb 20 | ||
Feb 21, 2024 | EVP, COO | -12.68K | $421.88 | -$5.35M | SELL | -16.71% | 63.18K | Feb 16 - Feb 20 | ||
Feb 21, 2024 | EVP, GLOBAL RESEARCH AND CSO | -10.56K | $421.88 | -$4.46M | SELL | -22.20% | 37.02K | Feb 16 - Feb 20 | ||
Feb 16, 2024 | EXECUTIVE CHAIRMAN | -9.01K | $419.10 | -$3.78M | SELL | -32.95% | 18.34K | Feb 14 - Feb 15 | ||
Feb 14, 2024 | EXECUTIVE CHAIRMAN | -3.39K | $419.42 | -$1.42M | SELL | -11.04% | 27.35K | Feb 12 - Feb 13 | ||
Feb 13, 2024 | EVP, CHIEF REG. & QUALITY OFF. | -2.41K | $422.41 | -$1.02M | SELL | -3.42% | 68.18K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | EVP CHIEF PATIENT & EXT AF OFF | -5.24K | $421.20 | -$2.21M | SELL | -6.09% | 80.93K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | EVP AND CHIEF LEGAL OFFICER | -3.33K | $420.67 | -$1.40M | SELL | -15.39% | 18.28K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | EVP, CHIEF TECHNICAL OPS. OFF. | -1.75K | $421.43 | -$735.40K | SELL | -7.01% | 23.14K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | EVP, COO | -7.47K | $421.30 | -$3.15M | SELL | -8.97% | 75.86K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | SVP & CHIEF ACCOUNTING OFFICER | -1.97K | $420.99 | -$827.25K | SELL | -16.88% | 9.68K | Feb 09 - Feb 12 | ||
Feb 13, 2024 | EVP, GLOBAL RESEARCH AND CSO | -5.24K | $421.24 | -$2.21M | SELL | -9.93% | 47.59K | Feb 09 - Feb 12 | ||
Jan 10, 2024 | EXECUTIVE CHAIRMAN | -6.65K | $419.07 | -$2.79M | SELL | -69.90% | 2.86K | Jan 08 | ||
Jan 04, 2024 | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $405.00 | -$1.22M | SELL | -6.42% | 43.69K | Jan 02 | ||
Dec 19, 2023 | CEO & PRESIDENT | 0.00 | $294.41 | -$3.86M | SELL-OPTIONS | 0.00% | 108.71K | Dec 15 | ||
Dec 15, 2023 | EXECUTIVE CHAIRMAN | -13.35K | $399.42 | -$5.33M | SELL | -58.40% | 9.51K | Dec 13 | ||
Dec 15, 2023 | CEO & PRESIDENT | -5.10K | $397.00 | -$2.02M | SELL | -4.48% | 108.71K | Dec 13 | ||
Dec 15, 2023 | EVP, COO | 0.00 | $293.26 | -$1.82M | SELL-OPTIONS | 0.00% | 56.70K | Dec 13 | ||
Nov 21, 2023 | EVP & CHIEF FINANCIAL OFFICER | -3.00K | $349.88 | -$1.05M | SELL | -6.04% | 46.69K | Nov 20 | ||
Nov 17, 2023 | EVP CHIEF PATIENT & EXT AF OFF | -35.00 | $369.92 | -$12.95K | SELL | -0.05% | 65.38K | Nov 15 | ||
Nov 17, 2023 | EVP, GLOBAL RESEARCH AND CSO | -19.00 | $369.92 | -$7.03K | SELL | -0.06% | 32.04K | Nov 15 | ||
Nov 16, 2023 | EVP AND CMO | -5.65K | $380.82 | -$2.15M | SELL | -16.17% | 29.30K | Nov 14 | ||
Nov 15, 2023 | CEO & PRESIDENT | -5.10K | $377.00 | -$1.92M | SELL | -4.29% | 113.81K | Nov 13 | ||
Nov 08, 2023 | DIRECTOR | 0.00 | $256.27 | -$2.90M | SELL-OPTIONS | 0.00% | 40.00K | Nov 06 | ||
Nov 02, 2023 | EVP AND CMO | -5.65K | $355.92 | -$2.01M | SELL | -13.92% | 34.95K | Oct 31 | ||
Oct 19, 2023 | EVP AND CMO | -5.65K | $373.25 | -$2.11M | SELL | -12.22% | 40.60K | Oct 17 | ||
Oct 19, 2023 | DIRECTOR | -243.00 | $375.00 | -$91.13K | SELL | -5.86% | 3.90K | Oct 17 | ||
Oct 18, 2023 | EXECUTIVE CHAIRMAN | -12.96K | $374.00 | -$4.85M | SELL | -36.18% | 22.86K | Oct 16 | ||
Oct 11, 2023 | DIRECTOR | -242.00 | $360.00 | -$87.12K | SELL | -5.52% | 4.14K | Oct 06 | ||
Oct 05, 2023 | EVP AND CMO | -5.65K | $345.28 | -$1.95M | SELL | -10.89% | 46.25K | Oct 03 | ||
Oct 03, 2023 | EVP AND CHIEF LEGAL OFFICER | -1.02K | $348.35 | -$354.62K | SELL | -8.79% | 10.57K | Sep 29 - Oct 02 | ||
Sep 21, 2023 | EVP AND CMO | -5.65K | $351.00 | -$1.98M | SELL | -9.82% | 51.91K | Sep 19 | ||
Sep 07, 2023 | EVP AND CMO | -5.65K | $352.66 | -$1.99M | SELL | -8.94% | 57.56K | Sep 05 | ||
Aug 25, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -2.50K | $355.00 | -$887.50K | SELL | -4.89% | 48.64K | Aug 23 | ||
Aug 14, 2023 | DIRECTOR | 0.00 | $238.77 | -$2.22M | SELL-OPTIONS | 0.00% | 6.54K | Aug 10 | ||
Aug 14, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -5.75K | $345.79 | -$1.99M | SELL | -10.11% | 51.14K | Aug 10 | ||
Aug 14, 2023 | EVP, CHIEF PATIENT OFFICER | -10.03K | $350.00 | -$3.51M | SELL | -13.30% | 65.38K | Aug 10 | ||
Aug 11, 2023 | EVP, GLOBAL RESEARCH AND CSO | -63.00 | $345.51 | -$21.77K | SELL | -0.20% | 32.04K | Aug 09 | ||
Aug 11, 2023 | DIRECTOR | -242.00 | $345.51 | -$83.61K | SELL | -5.23% | 4.39K | Aug 09 | ||
Jul 18, 2023 | DIRECTOR | 0.00 | $242.15 | -$2.58M | SELL-OPTIONS | 0.00% | 40.00K | Jul 17 | ||
Jul 18, 2023 | CEO & PRESIDENT | -7.83K | $355.00 | -$2.78M | SELL | -6.18% | 118.91K | Jul 17 | ||
Jun 20, 2023 | EVP, COO | 0.00 | $268.26 | -$1.39M | SELL-OPTIONS | 0.00% | 56.70K | Jun 15 | ||
Jun 01, 2023 | EVP, COO | -82.00 | $329.82 | -$27.05K | SELL | -0.14% | 56.70K | May 30 | ||
Jun 01, 2023 | SVP & CHIEF ACCOUNTING OFFICER | -289.00 | $329.82 | -$95.32K | SELL | -4.06% | 6.84K | May 30 | ||
May 09, 2023 | EVP, CELL & GENETIC THERAPIES | -3.27K | $350.00 | -$1.15M | SELL | -9.27% | 32.04K | May 05 - May 08 | ||
May 09, 2023 | EXECUTIVE CHAIRMAN | -2.00K | $349.25 | -$699.89K | SELL | -5.30% | 35.83K | May 05 - May 08 | ||
May 04, 2023 | EVP, CELL & GENETIC THERAPIES | -4.40K | $350.71 | -$1.54M | SELL | -11.09% | 35.31K | May 02 - May 03 | ||
May 04, 2023 | EXECUTIVE CHAIRMAN | -10.96K | $349.98 | -$3.84M | SELL | -22.46% | 37.83K | May 02 - May 03 | ||
May 03, 2023 | DIRECTOR | 588.00 | $348.28 | -$202.00K | GRANT | 14.55% | 4.63K | May 01 - May 02 | ||
May 01, 2023 | CEO & PRESIDENT | -3.32K | $339.08 | -$1.12M | SELL | -2.55% | 126.65K | Apr 27 | ||
Apr 14, 2023 | EVP, CELL & GENETIC THERAPIES | -7.57K | $326.70 | -$2.47M | SELL | -16.00% | 39.71K | Apr 12 | ||
Apr 14, 2023 | DIRECTOR | -1.21K | $199.44 | -$5.42M | SELL | -2.94% | 40.00K | Apr 12 - Apr 13 | ||
Apr 06, 2023 | EVP, CELL & GENETIC THERAPIES | -522.00 | $315.81 | -$164.85K | SELL | -1.09% | 47.28K | Apr 04 | ||
Mar 28, 2023 | EVP & CHIEF FINANCIAL OFFICER | -1.77K | $305.38 | -$539.91K | SELL | -3.44% | 49.61K | Mar 24 | ||
Mar 21, 2023 | EVP & CHIEF FINANCIAL OFFICER | -2.00K | $296.39 | -$592.79K | SELL | -3.75% | 51.38K | Mar 17 | ||
Mar 20, 2023 | EVP, CELL & GENETIC THERAPIES | -2.75K | $300.59 | -$825.42K | SELL | -5.28% | 49.27K | Mar 16 | ||
Mar 14, 2023 | EVP & CHIEF FINANCIAL OFFICER | -4.75K | $291.98 | -$1.39M | SELL | -8.18% | 53.38K | Mar 10 - Mar 13 | ||
Feb 28, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -3.66K | $288.96 | -$1.06M | SELL | -6.06% | 56.80K | Feb 24 - Feb 27 | ||
Feb 28, 2023 | EVP, COO | -9.75K | $288.27 | -$2.81M | SELL | -14.67% | 56.70K | Feb 24 - Feb 27 | ||
Feb 28, 2023 | SVP & CHIEF ACCOUNTING OFFICER | -1.71K | $288.01 | -$492.21K | SELL | -18.96% | 7.30K | Feb 24 - Feb 27 | ||
Feb 28, 2023 | EVP, GLOBAL RESEARCH AND CSO | -8.21K | $288.29 | -$2.37M | SELL | -20.39% | 32.04K | Feb 24 - Feb 27 | ||
Feb 24, 2023 | EVP, COO | -2.40K | $294.33 | -$706.68K | SELL | -3.49% | 66.44K | Feb 22 | ||
Feb 22, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -4.98K | $292.94 | -$1.46M | SELL | -7.61% | 60.47K | Feb 17 - Feb 21 | ||
Feb 22, 2023 | EVP, COO | -6.90K | $293.16 | -$2.02M | SELL | -9.11% | 68.84K | Feb 17 - Feb 21 | ||
Feb 22, 2023 | EVP, GLOBAL RESEARCH AND CSO | -7.75K | $293.33 | -$2.27M | SELL | -16.15% | 40.25K | Feb 17 - Feb 21 | ||
Feb 16, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -320.00 | $298.52 | -$95.53K | SELL | -0.49% | 65.44K | Feb 14 | ||
Feb 16, 2023 | EVP, CELL & GENETIC THERAPIES | -2.18K | $300.39 | -$655.16K | SELL | -3.52% | 59.73K | Feb 14 | ||
Feb 16, 2023 | EVP, COO | -6.40K | $298.68 | -$1.91M | SELL | -7.79% | 75.75K | Feb 14 | ||
Feb 16, 2023 | EVP, GLOBAL RESEARCH AND CSO | -6.40K | $298.70 | -$1.91M | SELL | -11.76% | 48.00K | Feb 14 | ||
Feb 14, 2023 | EVP, CHIEF REG. & QUALITY OFF. | -4.65K | $297.14 | -$1.38M | SELL | -6.60% | 65.77K | Feb 10 - Feb 13 | ||
Feb 14, 2023 | EVP, CELL & GENETIC THERAPIES | -5.36K | $297.64 | -$1.59M | SELL | -7.96% | 61.91K | Feb 10 - Feb 13 | ||
Feb 14, 2023 | EVP, COO | -14.25K | $297.56 | -$4.24M | SELL | -14.78% | 82.14K | Feb 10 - Feb 13 | ||
Feb 14, 2023 | EVP, GLOBAL RESEARCH AND CSO | -14.25K | $297.52 | -$4.24M | SELL | -20.76% | 54.40K | Feb 10 - Feb 13 | ||
Feb 08, 2023 | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $246.76 | -$154.48K | SELL-OPTIONS | 0.00% | 68.64K | Feb 06 | ||
Feb 02, 2023 | EVP, CELL & GENETIC THERAPIES | -106.00 | $325.00 | -$34.45K | SELL | -0.28% | 38.00K | Jan 31 | ||
Feb 02, 2023 | DIRECTOR | 0.00 | $198.57 | -$303.44K | SELL-OPTIONS | 0.00% | 41.21K | Jan 31 | ||
Jan 31, 2023 | DIRECTOR | -2.70K | $320.52 | -$865.41K | SELL | -39.42% | 4.15K | Jan 30 | ||
Jan 31, 2023 | DIRECTOR | 0.00 | $197.08 | -$357.09K | SELL-OPTIONS | 0.00% | 1.88K | Jan 27 | ||
Jan 27, 2023 | DIRECTOR | 0.00 | $194.14 | -$1.95M | SELL-OPTIONS | 0.00% | 1.88K | Jan 25 - Jan 26 | ||
Jan 27, 2023 | CEO & PRESIDENT | -10.00K | $315.05 | -$3.15M | SELL | -10.04% | 89.60K | Jan 25 | ||
Jan 25, 2023 | DIRECTOR | 0.00 | $192.30 | -$1.47M | SELL-OPTIONS | 0.00% | 1.88K | Jan 23 - Jan 24 | ||
Jan 19, 2023 | DIRECTOR | 0.00 | $192.09 | -$1.07M | SELL-OPTIONS | 0.00% | 1.88K | Jan 17 - Jan 18 | ||
Nov 17, 2022 | EVP, GLOBAL RESEARCH AND CSO | -34.00 | $308.61 | -$10.49K | SELL | -0.09% | 36.08K | Nov 15 | ||
Nov 09, 2022 | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $245.28 | -$150.51K | SELL-OPTIONS | 0.00% | 36.08K | Nov 07 | ||
Nov 03, 2022 | EVP, CELL & GENETIC THERAPIES | -1.09K | $312.78 | -$340.31K | SELL | -2.78% | 38.10K | Nov 01 - Nov 02 | ||
Oct 26, 2022 | DIRECTOR | -621.00 | $310.00 | -$192.51K | SELL | -13.32% | 4.04K | Oct 24 | ||
Oct 20, 2022 | EVP, CELL & GENETIC THERAPIES | -1.79K | $300.31 | -$537.86K | SELL | -4.37% | 39.19K | Oct 18 | ||
Aug 17, 2022 | CEO & PRESIDENT | -11.69K | $305.06 | -$3.57M | SELL | -10.50% | 99.60K | Aug 15 | ||
Aug 17, 2022 | EVP, COO | -15.60K | $229.75 | -$5.72M | SELL | -25.57% | 45.42K | Aug 15 | ||
Aug 17, 2022 | SVP, GENERAL COUNSEL | -3.75K | $303.90 | -$1.14M | SELL | -28.06% | 9.61K | Aug 15 | ||
Aug 12, 2022 | EVP, COO | -116.00 | $227.99 | -$44.12K | SELL | -0.19% | 61.02K | Aug 10 | ||
Aug 12, 2022 | SVP, GENERAL COUNSEL | -36.00 | $300.32 | -$10.81K | SELL | -0.27% | 13.35K | Aug 10 | ||
Aug 10, 2022 | DIRECTOR | -621.00 | $293.03 | -$181.97K | SELL | -11.76% | 4.66K | Aug 08 | ||
Aug 10, 2022 | SVP, GENERAL COUNSEL | -946.00 | $300.00 | -$283.80K | SELL | -6.60% | 13.39K | Aug 09 | ||
Aug 10, 2022 | EVP, CHIEF REG. & QUALITY OFF. | -1.40K | $298.97 | -$418.56K | SELL | -2.95% | 46.09K | Aug 09 | ||
Aug 10, 2022 | EVP, COO | -3.76K | $228.12 | -$1.41M | SELL | -5.80% | 61.14K | Aug 09 | ||
Aug 10, 2022 | EVP, GLOBAL RESEARCH AND CSO | 0.00 | $240.03 | -$136.93K | SELL-OPTIONS | 0.00% | 36.08K | Aug 08 | ||
Aug 02, 2022 | DIRECTOR | -621.00 | $278.77 | -$173.12K | SELL | -10.52% | 5.28K | Jul 29 | ||
Jul 27, 2022 | EXECUTIVE CHAIRMAN | -71.74K | $186.22 | -$31.67M | SELL | -96.16% | 2.86K | Jul 25 | ||
Jul 21, 2022 | EVP, GLOBAL RESEARCH AND CSO | -100.00 | $231.49 | -$2.06M | SELL | -0.28% | 36.08K | Jul 19 | ||
Jun 28, 2022 | CEO & PRESIDENT | -11.69K | $291.30 | -$3.41M | SELL | -9.52% | 111.15K | Jun 24 | ||
May 18, 2022 | EVP, CELL & GENETIC THERAPIES | -45.00 | $252.83 | -$11.38K | SELL | -0.11% | 41.75K | May 16 | ||
May 18, 2022 | EVP, COO | -133.00 | $251.19 | -$33.41K | SELL | -0.20% | 64.90K | May 16 | ||
May 18, 2022 | SVP, GENERAL COUNSEL | -133.00 | $252.88 | -$33.63K | SELL | -0.92% | 14.33K | May 16 | ||
May 06, 2022 | EVP, CELL & GENETIC THERAPIES | -36.00 | $275.09 | -$9.90K | SELL | -0.09% | 41.66K | May 04 | ||
May 04, 2022 | EVP, COO | -306.00 | $263.98 | -$80.78K | SELL | -0.47% | 64.90K | May 02 | ||
May 04, 2022 | EVP, CELL & GENETIC THERAPIES | -320.00 | $259.16 | -$82.93K | SELL | -0.76% | 41.70K | May 02 | ||
May 04, 2022 | DIRECTOR | -737.00 | $258.94 | -$190.84K | SELL | -11.10% | 5.90K | May 02 | ||
May 04, 2022 | EVP & CHIEF FINANCIAL OFFICER | -343.00 | $258.83 | -$88.78K | SELL | -0.80% | 42.73K | May 02 | ||
May 03, 2022 | SVP, GENERAL COUNSEL | -120.00 | $275.41 | -$33.05K | SELL | -0.83% | 14.33K | Apr 29 | ||
Apr 27, 2022 | SVP & CHIEF ACCOUNTING OFFICER | -327.00 | $269.55 | -$88.14K | SELL | -8.55% | 3.50K | Apr 25 | ||
Apr 20, 2022 | DIRECTOR | 0.00 | $182.89 | -$405.39K | SELL-OPTIONS | 0.00% | 1.88K | Apr 18 | ||
Apr 18, 2022 | DIRECTOR | 0.00 | $185.30 | -$415.04K | SELL-OPTIONS | 0.00% | 1.88K | Apr 14 | ||
Apr 14, 2022 | EXECUTIVE CHAIRMAN | -15.79K | $289.04 | -$4.56M | SELL | -17.47% | 74.60K | Apr 13 | ||
Apr 14, 2022 | DIRECTOR | 0.00 | $182.90 | -$810.90K | SELL-OPTIONS | 0.00% | 1.88K | Apr 12 - Apr 13 | ||
Apr 12, 2022 | DIRECTOR | 0.00 | $180.49 | -$791.58K | SELL-OPTIONS | 0.00% | 1.88K | Apr 08 - Apr 11 | ||
Apr 12, 2022 | DIRECTOR | 0.00 | $202.95 | -$294.61K | SELL-OPTIONS | 0.00% | 5.19K | Apr 08 | ||
Apr 12, 2022 | DIRECTOR | 0.00 | $203.88 | -$763.38K | SELL-OPTIONS | 0.00% | 1.10K | Apr 08 | ||
Apr 08, 2022 | DIRECTOR | 0.00 | $177.39 | -$766.80K | SELL-OPTIONS | 0.00% | 1.88K | Apr 06 - Apr 07 | ||
Apr 08, 2022 | EVP, CELL & GENETIC THERAPIES | -561.00 | $276.18 | -$154.93K | SELL | -1.29% | 42.78K | Apr 07 | ||
Apr 06, 2022 | EVP, CELL & GENETIC THERAPIES | -3.73K | $274.10 | -$1.02M | SELL | -7.91% | 43.34K | Apr 04 - Apr 05 | ||
Apr 06, 2022 | DIRECTOR | 0.00 | $175.82 | -$754.26K | SELL-OPTIONS | 0.00% | 1.88K | Apr 04 - Apr 05 | ||
Apr 05, 2022 | EVP & CHIEF FINANCIAL OFFICER | -2.58K | $264.76 | -$683.60K | SELL | -5.59% | 43.62K | Apr 01 | ||
Apr 04, 2022 | DIRECTOR | 0.00 | $194.90 | -$673.65K | SELL-OPTIONS | 0.00% | 1.10K | Mar 31 | ||
Mar 21, 2022 | EVP, CHIEF REG. & QUALITY OFF. | -2.83K | $250.11 | -$708.57K | SELL | -5.64% | 47.36K | Mar 17 | ||
Mar 21, 2022 | EVP & CHIEF FINANCIAL OFFICER | -3.17K | $250.15 | -$793.22K | SELL | -6.42% | 46.20K | Mar 17 | ||
Mar 21, 2022 | EVP, CELL & GENETIC THERAPIES | -2.12K | $250.06 | -$530.63K | SELL | -4.20% | 48.41K | Mar 17 | ||
Feb 28, 2022 | EVP, CHIEF REG. & QUALITY OFF. | -2.92K | $228.20 | -$665.22K | SELL | -5.49% | 50.19K | Feb 24 - Feb 25 | ||
Feb 28, 2022 | EVP, GLOBAL RESEARCH AND CSO | -13.61K | $229.60 | -$3.12M | SELL | -27.39% | 36.08K | Feb 24 - Feb 25 | ||
Feb 22, 2022 | EVP, CHIEF REG. & QUALITY OFF. | -4.63K | $232.34 | -$1.08M | SELL | -8.02% | 53.10K | Feb 17 - Feb 18 | ||
Feb 22, 2022 | EVP, GLOBAL RESEARCH AND CSO | -7.75K | $231.65 | -$1.80M | SELL | -13.49% | 49.69K | Feb 17 - Feb 18 | ||
Feb 16, 2022 | EVP, GLOBAL RESEARCH AND CSO | -2.44K | $232.02 | -$567.06K | SELL | -4.08% | 57.44K | Feb 14 | ||
Feb 14, 2022 | EVP, CHIEF REG. & QUALITY OFF. | -1.52K | $237.23 | -$360.60K | SELL | -2.57% | 57.74K | Feb 10 - Feb 11 | ||
Feb 14, 2022 | EVP, GLOBAL RESEARCH AND CSO | -5.82K | $236.66 | -$1.38M | SELL | -8.85% | 59.88K | Feb 10 - Feb 11 | ||
Feb 03, 2022 | EVP & CHIEF FINANCIAL OFFICER | 22.64K | $250.07 | -$736.21K | GRANT | 65.09% | 57.44K | Feb 01 - Feb 02 | ||
Feb 03, 2022 | EVP, CELL & GENETIC THERAPIES | 22.38K | $248.51 | -$389.17K | GRANT | 68.69% | 54.95K | Feb 01 - Feb 02 | ||
Feb 03, 2022 | EVP, GLOBAL RESEARCH AND CSO | 32.11K | $168.99 | -$768.66K | SELL-OPTIONS | 95.59% | 65.70K | Feb 01 - Feb 02 | ||
Feb 01, 2022 | DIRECTOR | 0.00 | $184.67 | -$571.26K | SELL-OPTIONS | 0.00% | 1.10K | Jan 28 | ||
Nov 16, 2021 | EVP, CHIEF PATIENT OFFICER | -51.00 | $187.19 | -$9.55K | SELL | -0.11% | 47.50K | Nov 15 | ||
Nov 16, 2021 | EVP, COO | -3.00 | $187.26 | -$561.78 | SELL | -0.01% | 41.24K | Nov 15 | ||
Nov 16, 2021 | EVP, GLOBAL RESEARCH AND CSO | -34.00 | $187.22 | -$6.37K | SELL | -0.10% | 33.59K | Nov 15 | ||
Aug 23, 2021 | CEO & PRESIDENT | 10.00K | $195.65 | $1.96M | BUY | 15.69% | 73.75K | Aug 19 | ||
Aug 04, 2021 | DIRECTOR | 15.00K | $197.91 | $2.97M | BUY | 57.23% | 41.21K | Aug 02 | ||
Jun 04, 2021 | DIRECTOR | -559.00 | $209.69 | -$117.22K | SELL | -9.72% | 5.19K | Jun 02 | ||
May 19, 2021 | EVP, CELL & GENETIC THERAPIES | -112.00 | $216.34 | -$24.23K | SELL | -0.33% | 34.11K | May 17 | ||
May 19, 2021 | EVP, CHIEF PATIENT OFFICER | -45.00 | $216.35 | -$9.74K | SELL | -0.09% | 47.50K | May 17 | ||
May 19, 2021 | SVP, GENERAL COUNSEL | -112.00 | $216.34 | -$24.23K | SELL | -1.34% | 8.25K | May 17 | ||
May 19, 2021 | EVP, CHIEF COMM & OPS OFFICER | -109.00 | $216.41 | -$23.59K | SELL | -0.26% | 41.24K | May 17 | ||
May 19, 2021 | EVP, GLOBAL RESEARCH AND CSO | -79.00 | $216.36 | -$17.09K | SELL | -0.23% | 33.59K | May 17 | ||
May 05, 2021 | EVP, CELL & GENETIC THERAPIES | -1.73K | $217.89 | -$376.07K | SELL | -4.82% | 34.11K | Apr 30 - May 03 | ||
Apr 29, 2021 | EVP, CHIEF PATIENT OFFICER | 0.00 | $151.29 | -$503.15K | SELL-OPTIONS | 0.00% | 47.50K | Apr 27 | ||
Apr 07, 2021 | EVP, CELL & GENETIC THERAPIES | -1.69K | $214.14 | -$361.05K | SELL | -4.49% | 35.83K | Apr 05 | ||
Mar 08, 2021 | SVP, GENERAL COUNSEL | -5.14K | $209.69 | -$1.08M | SELL | -38.38% | 8.25K | Mar 05 | ||
Mar 02, 2021 | SVP & CHIEF ACCOUNTING OFFICER | -5.00K | $211.88 | -$1.06M | SELL | -33.22% | 10.05K | Feb 26 - Mar 01 | ||
Feb 26, 2021 | SVP & CHIEF ACCOUNTING OFFICER | -1.94K | $215.29 | -$418.53K | SELL | -11.44% | 15.05K | Feb 24 - Feb 25 | ||
Feb 26, 2021 | EVP, CHIEF PATIENT OFFICER | -6.53K | $215.29 | -$1.41M | SELL | -12.09% | 47.50K | Feb 24 - Feb 25 | ||
Feb 26, 2021 | EVP, CHIEF ADM, LEG & BD OFF | -5.44K | $215.24 | -$1.17M | SELL | -15.01% | 30.84K | Feb 24 - Feb 25 | ||
Feb 26, 2021 | EVP, CHIEF COMMERCIAL OFFICER | -6.53K | $215.33 | -$1.41M | SELL | -13.67% | 41.24K | Feb 24 - Feb 25 | ||
Feb 26, 2021 | EVP, GLOBAL RESEARCH AND CSO | -5.44K | $215.24 | -$1.17M | SELL | -13.95% | 33.59K | Feb 24 - Feb 25 | ||
Feb 19, 2021 | SVP & CHIEF ACCOUNTING OFFICER | -7.04K | $211.80 | -$1.49M | SELL | -29.27% | 17.00K | Feb 17 - Feb 18 | ||
Feb 19, 2021 | EVP, CHIEF PATIENT OFFICER | -16.88K | $211.79 | -$3.57M | SELL | -23.80% | 54.03K | Feb 17 - Feb 18 | ||
Feb 19, 2021 | EVP, CHIEF ADM, LEG & BD OFF | -14.06K | $211.79 | -$2.98M | SELL | -27.94% | 36.28K | Feb 17 - Feb 18 | ||
Feb 19, 2021 | EVP, CHIEF COMMERCIAL OFFICER | -14.06K | $211.79 | -$2.98M | SELL | -22.74% | 47.77K | Feb 17 - Feb 18 | ||
Feb 19, 2021 | EVP, GLOBAL RESEARCH AND CSO | -14.06K | $211.80 | -$2.98M | SELL | -26.49% | 39.03K | Feb 17 - Feb 18 | ||
Feb 16, 2021 | SVP & CHIEF ACCOUNTING OFFICER | -1.50K | $210.57 | -$315.44K | SELL | -5.87% | 24.03K | Feb 11 | ||
Feb 16, 2021 | EVP, CELL & GENETIC THERAPIES | -1.69K | $210.56 | -$355.01K | SELL | -4.16% | 38.86K | Feb 11 | ||
Feb 16, 2021 | EVP, CHIEF PATIENT OFFICER | -4.46K | $210.55 | -$939.07K | SELL | -5.92% | 70.91K | Feb 11 | ||
Feb 16, 2021 | EVP, CHIEF ADM, LEG & BD OFF | -4.32K | $210.56 | -$909.18K | SELL | -7.90% | 50.35K | Feb 11 | ||
Feb 16, 2021 | EVP, CHIEF COMMERCIAL OFFICER | -5.16K | $210.55 | -$1.09M | SELL | -7.70% | 61.84K | Feb 11 | ||
Feb 16, 2021 | EVP, GLOBAL RESEARCH AND CSO | -5.28K | $210.54 | -$1.11M | SELL | -9.05% | 53.10K | Feb 11 | ||
Feb 09, 2021 | EVP, CHIEF ADM, LEG & BD OFF | 0.00 | $150.76 | -$247.97K | SELL-OPTIONS | 0.00% | 57.23K | Feb 05 | ||
Feb 05, 2021 | EVP, CHIEF ADM, LEG & BD OFF | 30.39K | $151.54 | -$52.02K | SELL-OPTIONS | 113.23% | 57.23K | Feb 03 | ||
Feb 05, 2021 | EVP, CHIEF COMMERCIAL OFFICER | 34.78K | $150.13 | -$197.69K | SELL-OPTIONS | 98.47% | 70.10K | Feb 03 | ||
Nov 18, 2020 | — | -42.00 | $223.53 | -$9.39K | SELL | -0.09% | 49.10K | Nov 16 | ||
Nov 18, 2020 | — | -91.00 | $223.53 | -$20.34K | SELL | -0.34% | 26.84K | Nov 16 | ||
Nov 18, 2020 | — | -7.00 | $223.64 | -$1.57K | SELL | -0.02% | 35.32K | Nov 16 | ||
Nov 18, 2020 | — | -38.00 | $223.47 | -$8.49K | SELL | -0.13% | 28.90K | Nov 16 | ||
Nov 12, 2020 | — | 15.00K | $217.36 | $3.26M | PURCHASE | 133.81% | 26.21K | Nov 10 | ||
Nov 06, 2020 | — | 0.00 | $152.13 | -$305.74K | OPTION EXERCISE | 0.00% | 26.84K | Nov 04 | ||
Nov 05, 2020 | — | 0.00 | $149.22 | -$194.75K | OPTION EXERCISE | 0.00% | 35.32K | Nov 03 |
PREGUNTAS FRECUENTES
¿Es legal el uso de información privilegiada?
Las operaciones con información privilegiada son legales siempre que se notifiquen a la Comisión de Bolsa y Valores (SEC). El comercio ilegal de valores se produce cuando la persona con información privilegiada viola un deber fiduciario o no informa de sus operaciones.
¿Cuáles son algunos ejemplos de manipulación del mercado?
Las operaciones con información privilegiada, los esquemas de pump and dump, el front running y las operaciones de lavado son ejemplos de manipulación del mercado. Los inversores que siguen el movimiento de activos con información privilegiada deben pensar atentamente por qué estos operadores con información privilegiada están negociando sus acciones antes de seguir adelante.
Explora operaciones con información privilegiada sobre todos los valores.